Kura Oncology insider Form 4 shows 82,500-share PSU vesting

Rhea-AI Filing Summary

Kura Oncology, Inc. reported an insider equity transaction by its Chief Medical Officer, Mollie Leoni. On 11/13/2025 she acquired 82,500 shares of common stock at a reported price of $0 following the vesting of performance-based restricted stock units tied to a development milestone. On 11/14/2025 she sold 15,485 shares of common stock at $11.1769 per share in a sell-to-cover transaction for taxes related to that vesting. After these transactions, she directly beneficially owned 225,454 shares of Kura Oncology common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Leoni Mollie

(Last) (First) (Middle)

C/O KURA ONCOLOGY, INC.

4930 DIRECTORS PLACE, SUITE 500

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kura Oncology, Inc. [ KURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/13/2025		A		82,500	A	$0	240,939	D
Common Stock	11/14/2025		S(1)		15,485	D	$11.1769	225,454	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sell-to-cover for taxes associated with the vesting of 1/6th of the underlying shares of performance-based restricted stock units ("PSUs") granted to the Reporting Person on May 31, 2023 and January 2, 2025. Each PSU represents the contingent right to receive one share of the Issuer's common stock based on the achievement of each of three specified development milestones, and the one-year anniversary of each milestone achievement, subject to the Reporting Person's continuous service on each corresponding vesting date. The performance criteria for one specified development milestone was determined to be met on November 13, 2025, resulting in the vesting of 1/6th of the underlying shares.

	Teresa Bair, Attorney-in-fact for Mollie Leoni	11/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Kura Oncology (KURA) report in this Form 4?

The filing reports that Chief Medical Officer Mollie Leoni acquired 82,500 shares of Kura Oncology common stock on 11/13/2025 from vesting of performance-based restricted stock units and sold 15,485 shares on 11/14/2025.

Why did the Kura Oncology CMO sell 15,485 shares of KURA stock?

The 15,485-share sale was described as a sell-to-cover for taxes associated with the vesting of 1/6th of the underlying shares of performance-based restricted stock units that vested when a specified development milestone was achieved.

At what prices were the Kura Oncology insider transactions reported?

The CMO acquired 82,500 shares of common stock at a reported price of $0 per share upon PSU vesting on 11/13/2025 and sold 15,485 shares at $11.1769 per share on 11/14/2025.

How many Kura Oncology (KURA) shares does the CMO own after these transactions?

Following the reported acquisition and tax-related sale, the Chief Medical Officer beneficially owned 225,454 shares of Kura Oncology common stock in direct ownership.

What triggered the vesting of performance-based restricted stock units at Kura Oncology?

The filing states that the performance criteria for one specified development milestone were met on 11/13/2025, which resulted in the vesting of 1/6th of the underlying shares of performance-based restricted stock units granted on May 31, 2023 and January 2, 2025.

What role does the reporting person hold at Kura Oncology (KURA)?

The reporting person, Mollie Leoni, is identified as an Officer of Kura Oncology and serves as the company’s Chief Medical Officer.